IKT
vs
S&P 500
IKT
S&P 500
Over the past 12 months, IKT has underperformed S&P 500, delivering a return of -55% compared to the S&P 500's +12% growth.
Stocks Performance
IKT vs S&P 500
Performance Gap
IKT vs S&P 500
Performance By Year
IKT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Inhibikase Therapeutics Inc
Glance View
Inhibikase Therapeutics, Inc. provides infectious disease treatments. The company is headquartered in Atlanta, Georgia and currently employs 6 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The firm's product candidates include IkT-148009, IkT-001pro, and IKT-01427. Its lead product candidate, IkT-148009 is for the treatment of PD and for the treatment of gastrointestinal (GI), complications that arise as early symptoms of PD in patients. The Company’s kT-148009 is a brain penetrant c-Abl protein kinase inhibitor that halts disease progression and reverses functional loss in the brain and reverses neurological dysfunction in the GI tract. Its product candidate IkT-001Pro, is a prodrug of the anticancer agent Imatinibm, and used as a treatment for chronic myelogenous leukemia (CML). IkT-01427 is an oral, brain-penetrant medication , designed to block the entry of the JC virus into the cell, thereby preventing the virus’ ability to replicate in the body.
